SEC Form 4 · accession 0001225208-19-000433

BOSTON SCIENTIFIC CORP · BSX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP & Pres, Interven Cardio

Period of report

Jan 1, 2019

Accepted (ET)

Jan 3, 2019 · 4:55 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000885725

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Nov 6, 2018	G	2,385	$0.00	D	69,623	D
Common Stock^F2,F1	Jan 1, 2019	M	21,502	$0.00	A	91,125	D
Common Stock^F1	Jan 1, 2019	F	6,762	$35.34	D	84,363	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance Share Units^F2,F3	$0.00	Jan 1, 2019	M	21,502	D	Dec 31, 2018	Dec 31, 2018	Common Stock	21,502	0	D

F1Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F2On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018.
F3Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

ballingerpoa.txt